Volume 8, Number 2—February 2002
Synopsis
Current Status of Antimicrobial Resistance in Taiwan
Table 2
Resistant pathogen | % of isolates |
|
---|---|---|
2,000 (12 hospitals) (clinical) | 2,000 (NTUH) (clinical/nosocomial) | |
Methicillin-resistant Staphylococcus aureus | 53-83 | 65/74 |
Erythromycin-resistant beta-hemolytic streptococci | 30-51 | 34/- |
Penicillin-nonsusceptible Streptococcus pneumoniae | 60-84 | 77/- |
Erythromycin-resistant S. pneumoniae | 67-100 | 89/- |
Gentamicin-resistant (high-level) enterococci | 36-54 | 48/54 |
Vancomycin-resistant enterococci | 1-3 | 3/2 |
Ampicillin-resistant H. influenzae | 45-73 | 61/- |
Cefotaxime-resistant Escherichia coli | 5-19 | 12/19 |
Ciprofloxacin-resistant E. coli | 11-33 | 20/29 |
Cefotaxime-resistant Klebsiella pneumoniae | 4-34 | 9/18 |
Ciprofloxacin-resistant K. pneumoniae | 5-33 | 9/16 |
Cefotaxime-resistant E. cloacae | 36-68 | 45/49 |
Ampicillin-resistant non-typhoid Salmonella | 44-69 | 56/- |
Cefotaxime-resistant non- typhoid Salmonella | 1-4 | 2/- |
Quinolone resistant non-typhi Salmonella | 0-16 | 0/- |
Ceftazidime-resistant Pseudomonas aeruginosa | 4-21 | 13/10 |
Imipenem-resistant P. aeruginosa | 3-16 | 14/10 |
Ciprofloxacin-resistant P. aeruginosa | 10-36 | 15/10 |
Imipenem-resistant Acinetobacter baumannii | 0-19 | 19/16 |
Ciprofloxacin-resistant A. baumannii | 54-74 | 54/42 |
aSusceptibility of these bacteria was determined by the standard disk-diffusion method.
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.